Paolo Martini

USPTO Granted Patents = 21 (Patent Applications = 14)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 64(Granted Patents)

Location History:

Boston, MA (US) (2013 - 2023)
Cambridge, MA (US) (2019 - 2023)

Company Filing History:

Shire Human Genetic Therapies, Inc.

patents

1 out of 25

Synageva Biopharma Corporation

patents

4. 1 out of 10

Fundacion Para La Investigacion Medica Aplicada

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12377136 - Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria (2025-08-05),

2. 12252704 - Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 (2025-03-18),

3. 12239742 - Polynucleotides encoding Citrin for the treatment of Citrullinemia type 2 (2025-03-04),

4. 12128113 - Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome (2024-10-29),

5. 12123030 - Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia (2024-10-22),

6. 11801227 - Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis (2023-10-31),

7. 11649461 - Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease (2023-05-16),

8. 11504337 - Polynucleotides encoding methylmalonyl-CoA mutase (2022-11-22),

9. 11065307 - Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety (2021-07-20),

10. 11001861 - Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 (2021-05-11),

11. 10993918 - Polynucleotides encoding citrin for the treatment of Citrullinemia type 2 (2021-05-04),

12. 10519455 - Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease (2019-12-31),

13. 10494636 - Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease (2019-12-03),

14. 10426738 - Polynucleotides encoding methylmalonyl-CoA mutase (2019-10-01),

15. 10406112 - Polynucleotides encoding methylmalonyl-CoA mutase (2019-09-10),

Title: The Innovative Mind of Paolo Martini

Introduction: Paolo Martini, a brilliant inventor based in Boston, MA, is known for his groundbreaking contributions to the field of technology and innovation. His passion for creating solutions to complex problems has led to numerous patents and advancements in various industries.

Latest Patents: Paolo Martini's recent patents include a cutting-edge artificial intelligence algorithm for predictive analytics, a revolutionary medical device for non-invasive diagnostics, and a sustainable energy solution for urban environments.

Career Highlights: With a background in engineering and computer science, Paolo Martini has worked for leading tech companies, where he honed his skills in research and development. His expertise in machine learning and data analysis has been instrumental in developing innovative products that have transformed industries.

Collaborations: Paolo Martini has collaborated with top researchers and scientists from renowned universities and research institutions worldwide. His collaborative projects have resulted in groundbreaking inventions that have received international recognition.

Conclusion: Paolo Martini's relentless pursuit of innovation and his dedication to pushing the boundaries of technology make him a true visionary in the world of inventors. His impact on various fields is profound, and his legacy as a pioneering inventor continues to inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.